Left ventricular hypertrophy and outcomes: A five-year retrospective analysis of patients with essential hypertension
https://doi.org/10.18705/1607-419X-2012-18-5-385-397
Abstract
Left ventricular hypertrophy (LVH) is the most important element of cardiovascular continuum in patients with essential hypertension (EH). The results of a five-year retrospective analysis of EH patients cohort with initially different types of left ventricular geometry (491 subjects) are presented. It is shown that the overall mortality in patients with concentric and eccentric LVH does not differ significantly (37 and 35 %, respectively) but exceeds that in subjects with normal LV geometry (20 %). Associated and concomitant pathology determine the total and cardiovascular prognosis more in patients with concentric LVH than in subjects with eccentric LVH. The presence of ECG valid quantitative and strain diagnostic LVH criteria (Sokolow-Lyon index and Perugian university sign) determines the worst remote prognosis in patients with both concentric and eccentric LVH. The enlarged size of the left atrium is an universal marker of poor outcome in hypertensive patients regardless the type оf left ventricular geometry.
About the Authors
A. V. Barsukov
Military Medical Academy named after S.M. Kirov
Russian Federation
Russian Federation
M. P. Zobnina
Military Medical Academy named after S.M. Kirov
Russian Federation
Russian Federation
M. S. Talantseva
Military Medical Academy named after S.M. Kirov
Russian Federation
Russian Federation
References
1. Конради А.О. Ремоделирование сердца и крупных сосудов при гипертонической болезни: автореф. дис.. д-ра мед. наук. — СПб., 2003. — 31 с.
2. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension // Circulation. — 1998. — Vol. 97, № 1. — P. 345-352.
3. Vakili B., Okin P., Devereux R. Prognostic implications of left ventricular hypertrophy // Am. Heart J. — 2001. — Vol. 141, № 3. — P. 334-341.
4. Cuspidi C. Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height(2.7) // Hypertension. — 2009. — Vol. 27, № 12. — P. 2465-2471.
5. Mureddu G.F., Cioffi G., Stefenelli C., Boccanelli A., de Simone G. Compensatory or inappropriate left ventricular mass in different models of left ventricular pressure overload: comparison between patients with aortic stenosis and arterial hypertension // J Hypertens. — 2009. — Vol. 27, № 3. — P. 642-649.
6. Preis S.R. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study // Circulation. — 2009. — Vol. 120, № 3. — P. 212-220.
7. Tsioufis C., Vezali E., Tsiachris D. et al. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. Original papers // Epidemiology. — 2009. — Vol. 27, № 4. — P. 744-752.
8. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Fremingham heart study // N. Engl. J. Med. — 1990. — Vol. 322, № 22. — P. 1561-1566.
9. Lieb W. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study // Circulation. — Vol. 2009. — Vol. 119, № 24. — P. 3085-3092.
10. Larstorp A.C.K., Okin P.M., Devereux R.B. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; the LIFE study // Am. J. Hypertens. — 2012. — Vol. 25, № 10. — P. 1101-1109.
11. Brandt M.C., Mahfoud F., Reda S. et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension // J. Am. Coll. Cardiol. — 2012. — Vol. 59, № 10. — P. 901-909.
12. Barsukov A., Bagaeva Z., Shustov S. Electrocardiographic data in essential hypertensive patients with different types of left ventricular hypertrophy // J. Hypertens. — 2010. — Vol. 28. — P. e367.
13. Barsukov A., Bagaeva Z., Lokshina T., Kitsyshin V., Shus-tov S. Echocardio-graphic data in overweight essential hypertensive patients with different types of left ventricular hypertrophy // J. Hypertens. — 2010. — Vol. 28. — P. e568.
14. Багаева З.В. Клинико-анамнестические, гемодинами-ческие и нейрогуморальные аспекты ремоделирования левого желудочка при гипертонической болезни: Автореф. дис. канд. мед. наук. — СПб., 2011. — 22 с.
15. Dahlof B., Zanchetti A., Diez J. et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy // J. Hypertens. — 2002. — Vol. 20, № 9. — P. 1855-1864.
16. Julius S., Kjeldsen S.E., Weber M. et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. — 2004. — Vol. 363, № 9426. — P. 2022-2031.
17. Yusuf S., Teo K., Anderson C. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. — 2008. — Vol. 372, № 9644. — P. 1174-1183.
18. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension // Ann. Intern. Med. — 1991. — Vol. 114, № 5. — P. 345-352.
19. Krumholz H.M., Larson M., Levy D. Prognosis of left ventricular geometric pat-terns in the Framingham Heart Study // J. Am. Coll. Cardiol. — 1995. — Vol. 25, № 4. — P. 879-884.
20. Ghali J., Kadakia S., Cooper R., Liao Y.L. Impact of left ventricular hypertrophy patterns on ventricular arrhythmias in the absence of coronary artery disease // J. Am. Coll. Cardiol. — 1991. — Vol. 17, № 6. — P. 1277-1282.
21. Конради А.О. Лечение артериальной гипертензии в особых группах больных. Гипертрофия левого желудочка // Артериальная гипертензия. — 2005. — T. 11, № 2. — С. 105-109.
22. Williamson D.F., Pamuk E., Thun M., Flanders D., Byers T., Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years // Am. J. Epidemiol. — 1995. — Vol. 141, № 12. — P. 1128-1141.
23. Knuiman M.W., Vu H.T. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores // J. Epidemiol. Community Health. — 1997. — Vol. 51, № 5. — P. 515-519.
24. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet. — 2004. — Vol. 364, № 9438. — P. 937-952.
25. Casale P.N., Devereux R.B., Milner M. et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hyper-tensive men // Ann. Intern. Med. — 1986. — Vol. 105, № 2. — P. 173-178.
26. Kaul P., Armstrong P., Chang W. et al. Long-tеrm mortality of patients with acute myocardial infarction in the United States and Canada (Comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I) // Circulation. — 2004. — Vol. 110, № 13. — P. 1754-1760.
27. Verdecchia P., Reboldi G., Angeli F. et al. Prognostic value of serial electrocardi-ographic voltage and repolarization changes in essential hypertension: the HEART Survey study // Am. J. Hypertens. — 2007. — Vol. 20, № 9. — P. 997-1004.
28. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study // Am. J. Med. — 1995. — Vol. 98, № 5. — P. 476-484.
29. Healey J.S., Connolly S.J. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target // Am. J. Cardiol. — 2003. — Vol. 91, № 10А. — P. 9G-14G.
30. Wachtell K. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Cardiol. — 2005. — Vol. 45, № 5. — P. 712-719.
31. Benjamin E.J., Wolf P.A., DAgostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on risk of death. The Framingham Heart Study // Circulation. — 1998. — Vol. 98, № 10. — P. 946-952.
32. Дедов И.И. Диабет как фактор риска сердечнососудистых заболеваний // Сердечная недостаточность. — 2003. — № 1. — С. 12-15.
33. Gu K., Cowie C.C., Harris M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993 // Diabetes Care. — 1998. — Vol. 21, № 7. — P. 1138-1145.
34. Конради А.О. Структурно-функциональные параметры миокарда у больных гипертонической болезнью в зависимости от массы тела, типа ожирения и состояния углеводного обмена // Артериальная гипертензия. — 2002. — Т. 8, № 2. — С. 12-16.
35. Онучина Е.Л. Нарушения ритма сердца у пациентов с сахарным диабетом 2 типа // Сахарный диабет. — 2008. — Т. 38, № 1. — С. 25-28.
36. Барсуков А.В., Свеклина Т.С., Суюндикова М.Г., Шустов С.Б., Козлов В.А., Карулина Л.Ю. К вопросу о субклиническом поражении органов-мишеней у больных артериальной гипертензией, страдающих сахарным диабетом и фибрилляцией предсердий // Мат. Всероссийской научнопрактической конференции «Актуальные вопросы внутренней медицины». — СПб., 2010. — С. 25-29.
37. Palmieri V. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects. Hypertension genetic epidemiology network (HyperGEN) study // Circulation. — 2001. — Vol. 103, № 1. — P. 102-107.
38. Соколов Е.И. Диабетическое сердце — М. : Медицина, 2002. — 415 с. / Sokolow E.I. Diabetic heart. — M. : Medicine [Meditsina], 2002. — 415 p. [Russian].
39. Dawson A., Orrius A.D., Struthers A.D. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus // Diabe-tologia. — 2005. — Vol. 48, № 10. — Р. 1971-1979.
40. Menotti A., Lanti M., Kafatos A. et al. The role of a baseline casual blood pressure measurement and of blood pressure changes in middle age in prediction of cardiovascular and all-cause mortality occurring late in life: a cross-cultural comparison among the European cohorts of the Seven Countries Study // J. Hypertens. — 2004. — Vol. 22, № 9. — P. 1683-1690.
41. Brown D.W., Giles W.H., Croft J.B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension // Am. Heart J. — 2000. — Vol. 140, № 6. — Р. 848-856.
42. East M.A., Jollis J.G., Nelson C.L., Marks D., Peterson E.D. The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: do race and gender matter? // J. Am. Coll. Cardiol. — 2003. — Vol. 41, № 6. — Р. 949-954.
43. Okin P., Kjeldsen S., Julius S. et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy // Eur. Heart J. — 2010. — Vol. 31, № 18. — P. 2271-2279.
44. Aronow W.S., Frishman W.H. Management of hyperсholesterinemia in older persons for the prevention of cardiovascular disease // Cardiol. Rev. — 2010. — Vol. 13, № 3. — P. 132-140.
45. Wong N.D., Wilson P.W., Kannel W.B. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study // Ann. Intern. Med. — 1991. — Vol. 115, № 9. — P. 687-693.
46. Julien J., Tranche C., Souchet T. Left ventricular hypertrophy in hypertensive patients. Epidemiology and prognosis // Arch. Mal. Coeur. Vaiss. — 2004. — Vol. 97, № 3. — P. 221-227.
47. Козиолова Н.А., Шатунова О.А., Лазарев И.А. Факторы риска развития гипертрофии левого желудочка у больных гипертонической болезнью при высокой приверженности к лечению // Кардиология. — 2012. — Т. 52, № 4. — С. 25-30.
48. Bahrami H., Bluemke D., Kronmal R. et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity the MESA (Multi-Ethnic Study of Atherosclerosis) study // J. Am. Coll. Cardiol. — 2008. — Vol. 51, № 18. — P. 1775-1783.
49. Desai C.S., Ning H., Lloyd-Jones D.M. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study // Heart. — 2012. — Vol. 98, № 4. — P. 330-334.
50. Okin P.M., Oikarinen L., Viitasalo M. et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) // Circulation. — 2009. — Vol. 119, № 14. — P.1883-1891.
51. Benjamin E.J., D’Agostino R.B., Belanger A.J. et al. Left atrial size and the risk of stroke and death. The Framingham Heart Study // Circulation. — 1995. — Vol. 92, № 4. — P. 835-841.
52. Lip G., Kamath S. The left atrium in hypertension: a symbol of mortality and morbidity? // Sem. Cardiol. — 2003. — Vol. 9, № 2. — P. 9-12.
Review
For citations:
Barsukov A.V., Zobnina M.P., Talantseva M.S. Left ventricular hypertrophy and outcomes: A five-year retrospective analysis of patients with essential hypertension. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(5):385-397. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-5-385-397
Views:
8730
Email this article 